Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, announced that the Company’s management will participate and host investor meetings in the following upcoming September 2021 virtual investor conferences.
ROCKVILLE, Md., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company’s management will participate and host investor meetings in the following upcoming September 2021 virtual investor conferences.
Citi’s 16th Annual BioPharma Virtual Conference
Date: Thursday, September 9, 2021
Participation Type: One-on-one meetings
Wells Fargo 2021 Virtual Healthcare Conference
Date: Friday, September 10, 2021
Participation Type: Presentation
Presentation Time: 9:20 a.m. ET
Morgan Stanley 19th Annual Global Healthcare Conference
Date: Wednesday, September 15, 2021
Participation Type: Fireside Chat
Presentation Time: 11:45 a.m. ET
A live webcast of the events can be accessed by visiting Events & Presentations in the Investor Relations section on the Company’s website at www.supernus.com. An archived replay of each webcast will be available for 60 days on the Company’s website after the respective conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, ADHD, hypomobility in Parkinson’s disease, cervical dystonia and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for hypomobility in Parkinson’s disease, epilepsy, depression and rare CNS disorders.
For more information, please visit www.supernus.com.
CONTACTS:
Jack A. Khattar, President and Chief Executive Officer
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
Westwicke/ICR
Office: (443) 213-0505
Mobile: (443) 377-4767
Email: peter.vozzo@westwicke.com
